+1 858-523-8231
Login | Register
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
Home Aldehydes 80360-20-9
80360-20-9,MFCD02681985
Catalog No.:AA003D18

80360-20-9 | 1-(Phenylsulfonyl)-1h-indole-3-carbaldehyde

Pack Size
Purity
Availability
Price(USD)
Quantity
  
100mg
97%
in stock  
$27.00   $19.00
- +
250mg
97%
in stock  
$42.00   $29.00
- +
1g
97%
in stock  
$82.00   $57.00
- +
5g
97%
in stock  
$262.00   $184.00
- +
  • Technical Information
  • Properties
  • Upstream Synthesis Route
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Upstream Synthesis Route
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA003D18
Chemical Name:
1-(Phenylsulfonyl)-1h-indole-3-carbaldehyde
CAS Number:
80360-20-9
Molecular Formula:
C15H11NO3S
Molecular Weight:
285.3177
MDL Number:
MFCD02681985
SMILES:
O=Cc1cn(c2c1cccc2)S(=O)(=O)c1ccccc1
NSC Number:
628191
Properties
Properties
 
Form:
Solid  
MP:
157-161 °C(lit.)  
Storage:
Inert atmosphere;2-8℃;  

Computed Properties
 
Complexity:
450  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
20  
Hydrogen Bond Acceptor Count:
3  
Rotatable Bond Count:
3  
XLogP3:
2.7  

Upstream Synthesis Route

[1]Synlett,1999,#6,p.786-788

[2]EuropeanJournalofMedicinalChemistry,2012,vol.53,p.283-291

[3]JournalofOrganicChemistry,2002,vol.67,#3,p.1001-1003

[4]SyntheticCommunications,2007,vol.37,#5,p.829-837

[5]Tetrahedron,1998,vol.54,#46,p.13915-13928

[6]JournalofOrganicChemistry,2005,vol.70,#15,p.5840-5851

[7]SyntheticCommunications,1996,vol.26,#8,p.1525-1538

[8]Heterocycles,2011,vol.82,#2,p.1617-1631

[9]Tetrahedron,1999,vol.55,#19,p.6243-6260

[10]JournaloftheAmericanChemicalSociety,1988,vol.110,p.7188

[11]IndianJournalofChemistry-SectionBOrganicandMedicinalChemistry,2006,vol.45,#11,p.2469-2473

[12]JournalofOrganicChemistry,2011,vol.76,#6,p.1554-1561

[13]Chemicalandpharmaceuticalbulletin,1987,vol.35,#6,p.2261-2265

[14]TetrahedronLetters,1983,vol.24,#49,p.5435-5438

[15]Tetrahedron,1999,vol.55,#33,p.10135-10154

[16]Synlett,1997,vol.1997,#3,p.289-290

[17]Tetrahedron,1998,vol.54,#14,p.3549-3566

[18]EuropeanJournalofMedicinalChemistry,2010,vol.45,#11,p.5428-5437

[19]ChemicalBiologyandDrugDesign,2014,vol.83,#2,p.224-236

[20]TetrahedronLetters,2010,vol.51,#2,p.238-239

[21]ChemicalandPharmaceuticalBulletin,2009,vol.57,#5,p.536-540

[22]Patent:WO2011/109059,2011,A1,.Locationinpatent:Paragraph0045;00391

[23]JournalofMedicinalChemistry,2012,vol.55,#16,p.7285-7289,5

[24]JournalofMedicinalChemistry,2012,vol.55,#16,p.7285-7289

[25]Patent:WO2014/138279,2014,A1,.Locationinpatent:Paragraph00247

[26]JournalofOrganicChemistry,1984,vol.49,#23,p.4518-4523

[27]JournalofOrganicChemistry,1992,vol.57,#22,p.5878-5891

[28]ChemistryofHeterocyclicCompounds,2000,vol.36,#10,p.1141-1148

[29]BioorganicandMedicinalChemistryLetters,2007,vol.17,#8,p.2342-2346

[30]JournalofMedicinalChemistry,2007,vol.50,#18,p.4548-4552

[31]BioorganicandMedicinalChemistryLetters,2010,vol.20,#24,p.7274-7277

[32]OrganicLetters,2013,vol.15,#15,p.3910-3913

[33]ACSMedicinalChemistryLetters,2015,vol.6,#9,p.993-997

[34]Patent:WO2016/14797,2016,A1,.Locationinpatent:Page/Pagecolumn39

[35]BioorganicandMedicinalChemistryLetters,2016,vol.26,#18,p.4403-4407

[36]SyntheticCommunications,2016,vol.46,#23,p.1902-1908

[37]JournalofMedicinalChemistry,2017,vol.60,#5,p.1843-1859

[38]Molecules,2017,vol.22,#6,

[39]OrganicandBiomolecularChemistry,2017,vol.15,#35,p.7404-7410

[40]Patent:CN107522650,2017,A,.Locationinpatent:Paragraph0021

[41]Patent:WO2004/48330,2004,A1,.Locationinpatent:Page44

[1]RSCAdvances,2016,vol.6,#18,p.14547-14551

[1]JournalofOrganicChemistry,2002,vol.67,#17,p.6268-6271

[1]JournalofOrganicChemistry,2002,vol.67,#17,p.6268-6271

[1]JournalofOrganicChemistry,1982,vol.47,#5,p.757-761

[2]JournalofOrganicChemistry,2013,vol.78,#6,p.2362-2372

Downstream Synthesis Route

[1]TetrahedronLetters,1990,vol.31,p.3347-3350

[1]JournalofOrganicChemistry,1991,vol.56,p.6292-6298

[1]Tetrahedron,1991,vol.47,p.7911-7924

[1]Synlett,1999,p.786-788

[2]EuropeanJournalofMedicinalChemistry,2012,vol.53,p.283-291

[3]Tetrahedron,2021,vol.79

[4]JournalofOrganicChemistry,2002,vol.67,p.1001-1003

[5]SyntheticCommunications,2007,vol.37,p.829-837

[6]Arkivoc,2019,vol.2019,p.368-375

[7]Tetrahedron,1998,vol.54,p.13915-13928

[8]JournalofOrganicChemistry,2005,vol.70,p.5840-5851

[9]SyntheticCommunications,1996,vol.26,p.1525-1538

[10]Heterocycles,2011,vol.82,p.1617-1631

[11]Tetrahedron,1999,vol.55,p.6243-6260

[12]JournaloftheAmericanChemicalSociety,1988,vol.110,p.7188

[13]IndianJournalofChemistry-SectionBOrganicandMedicinalChemistry,2006,vol.45,p.2469-2473

[14]JournalofOrganicChemistry,2011,vol.76,p.1554-1561

[15]Chemicalandpharmaceuticalbulletin,1987,vol.35,p.2261-2265

[16]TetrahedronLetters,1983,vol.24,p.5435-5438

[17]Tetrahedron,1999,vol.55,p.10135-10154

[18]Patent:CN109776528,2019,A.Locationinpatent:Paragraph0023-0028

[19]Synlett,1997,vol.1997,p.289-290

[20]Tetrahedron,1998,vol.54,p.3549-3566

[21]EuropeanJournalofMedicinalChemistry,2010,vol.45,p.5428-5437

[22]ChemicalBiologyandDrugDesign,2014,vol.83,p.224-236

[23]Patent:CN111333634,2020,A.Locationinpatent:Paragraph0063;0069-0072

[24]TetrahedronLetters,2010,vol.51,p.238-239

[25]ChemicalandPharmaceuticalBulletin,2009,vol.57,p.536-540

[26]Patent:WO2011/109059,2011,A1.Locationinpatent:Paragraph0045;00391

[27]Patent:WO2014/138279,2014,A1.Locationinpatent:Paragraph00247

[28]JournalofMedicinalChemistry,2012,vol.55,p.7285-7289,5

[29]JournalofOrganicChemistry,1984,vol.49,p.4518-4523

[30]JournalofOrganicChemistry,1992,vol.57,p.5878-5891

[31]ChemistryofHeterocyclicCompounds,2000,vol.36,p.1141-1148

[32]BioorganicandMedicinalChemistryLetters,2007,vol.17,p.2342-2346

[33]JournalofMedicinalChemistry,2007,vol.50,p.4548-4552

[34]BioorganicandMedicinalChemistryLetters,2010,vol.20,p.7274-7277

[35]OrganicLetters,2013,vol.15,p.3910-3913

[36]ACSMedicinalChemistryLetters,2015,vol.6,p.993-997

[37]Patent:WO2016/14797,2016,A1.Locationinpatent:Page/Pagecolumn39

[38]BioorganicandMedicinalChemistryLetters,2016,vol.26,p.4403-4407

[39]SyntheticCommunications,2016,vol.46,p.1902-1908

[40]JournalofMedicinalChemistry,2017,vol.60,p.1843-1859

[41]Molecules,2017,vol.22

[42]OrganicandBiomolecularChemistry,2017,vol.15,p.7404-7410

[43]Patent:CN107522650,2017,A.Locationinpatent:Paragraph0021

[44]Patent:WO2004/48330,2004,A1.Locationinpatent:Page44

[45]EuropeanJournalofMedicinalChemistry,2019,vol.166,p.108-118

[46]PharmaceuticalChemistryJournal,2020,vol.54,p.345-352

[47]BioorganicChemistry,2021,vol.116

[1]MonatsheftefurChemie,1989,vol.120,p.157-162

Literature

Title: Concise total synthesis of (+/-)-pseudotabersonine via double ring-closing metathesis strategy.

Journal: Organic letters 20100820

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 80360-20-9
116325-17-8

116325-17-8

 278593-17-2

278593-17-2

 117954-70-8

117954-70-8

 50562-79-3

50562-79-3

 468717-73-9

468717-73-9

 651331-50-9

651331-50-9
Building Blocks
More >
Tags:80360-20-9 Molecular Formula|80360-20-9 MDL|80360-20-9 SMILES|80360-20-9 1-(Phenylsulfonyl)-1h-indole-3-carbaldehyde